The majority of patients with grade 2 gliomas have mutations in the gene that controls an enzyme called isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2). This gene makes a protein that makes tumours grow. Vorasidenib is a medication that acts on these IDH mutations. A recent study (INDIGO trial) that included over 300 patients with grade 2 glioma with the IDH mutation showed that the drug significantly slowed tumour growth in the patients taking vorasidenib compared with those patients taking an inactive placebo. This is a very important study as it suggests there may be a new treatment for these types of gliomas. As of June 2024 Vorasidenib is not yet available in Australia.
We have provided two PDF files about this study below if you would like more information:
- A 1-page summary of the research.
- The full text research paper.
The Brain Tumour Charity, UK, provides a lay summary.